Senhwa Biosciences Appoints Lucas S. Chang as General Counsel

News provided by

Dec 14, 2016, 09:00 ET

TAIPEI, Taiwan and SAN DIEGO, Dec. 14, 2016 /PRNewswire/ -- Senhwa Biosciences, Inc. announced the appointment of Lucas S. Chang as Vice President - General Counsel today. Lucas S. Chang has assumed the role on 1^st December, 2016 and is based at Senhwa's US office in San Diego.

Mr. Chang joins Senhwa's senior management team from multinational law firm Morgan, Lewis & Bockius LLP, where he was until recently a senior partner of the firm's Greater China Practice and the Chief Representative in Beijing. Mr. Chang has expertise in corporate transactions (including mergers and acquisitions), corporate governance, IP creation and licensing. He counsels clients of diversified industries covering biotechnology, pharmaceutics, semiconductor, electronics, etc. Mr. Chang has significant experience in the US, Asia and the Greater China region. He is an IP expert and is also well experienced in IP litigation.

Mr. Benny Hu, Chairman of Senhwa Biosciences Inc., said: "I am delighted to welcome Lucas to our team at a time Senhwa is undergoing tremendous growth. Lucas will bring to Senhwa over 20 years of experience on the protection and strategic management of IP and information assets. His extensive experience in licensing and strategic transactions will be invaluable, and will further strengthen our corporate governance."

Before launching his legal career, Mr. Chang was a technologist in Union Carbide Corporation Technical Center and IBM. He obtained a B.S.E degree and a Ph.D. degree in chemical engineering before getting his J.D. degree from Santa Clara University, School of Law in 1994. Mr. Chang is a member of the State Bar of California and licensed to practice before the USPTO.

About Senhwa Biosciences

Senhwa Biosciences identifies and develops innovative therapies that have the potential to fundamentally change the way patients are treated. Our central philosophy is to unearth validated targets or therapies that could significantly improve treatment, but have not yet been properly exploited. As a value-added development company, Senhwa aims to take innovative therapies that could impact the current standard of care and drive them through clinical Proof-of-Concept.

Senhwa has a strong Management Team with proven track records in developing new drugs and targeted agents. Headquartered in Taiwan, but with a vital operational base in San Diego, California, the Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global Investigators and service providers. Clinical trials are ongoing or planned for Australia and the US, and service providers work from their bases in North America, Asia, Australia and Europe. For more information on Senhwa and its programs, please visit www.senhwabio.com.

SOURCE Senhwa Biosciences, Inc.